Pharma AI|30 Mar 2026
Eli Lilly signed a licensing and AI drug discovery collaboration with Insilico Medicine.
The Story
The total transaction value is estimated up to $2.75 billion.
Why It Matters
This isn't just another tech headline. A major pharma player just put serious money into AI for core drug discovery. For smaller players, this means AI is no longer optional; it's the new standard for pipeline efficiency. Your competitors will be leveraging this.
What To Do About It
Don't chase shiny new tools. Start by auditing your existing data and processes for AI readiness. I can help you identify high-impact, low-risk areas to pilot AI within your current Microsoft 365 environment, compliant with EU AI Act.
small pharma AICRO artificial intelligencelife sciences SMB AIpharma GDPR AIbiotech startup AI compliance
